The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is a critical pro-survival cascade in dopaminergic neurons, governing cellular energy metabolism, protein homeostasis, mitochondrial function, and resistance to apoptosis. In Parkinson's disease (PD), this pathway intersects with multiple disease-relevant mechanisms including alpha-synuclein aggregation, mitochondrial dysfunction (PINK1/Parkin), LRRK2 signaling, and neuroinflammation. Understanding PI3K/Akt dysregulation in PD provides insight into disease mechanisms and identifies potential therapeutic targets for neuroprotection.
¶ PI3K Activation and Membrane Recruitment
In the substantia nigra pars compacta (SNc), PI3K/Akt signaling is activated by multiple upstream signals essential for dopaminergic neuron survival:
- Brain-derived neurotrophic factor (BDNF): BDNF binds to TrkB receptors, activating PI3K/Akt signaling. BDNF supports dopaminergic neuron survival, and reduced BDNF signaling contributes to PD pathogenesis.
- Glial cell line-derived neurotrophic factor (GDNF): GDNF activates Ret receptor tyrosine kinase, strongly inducing PI3K/Akt signaling. GDNF delivery has been explored in clinical trials for PD neuroprotection.
- Insulin and IGF-1: Insulin receptors and IGF-1 receptors couple to IRS-1/2 and activate PI3K. Brain insulin resistance is increasingly recognized in PD, similar to Alzheimer's disease "type 3 diabetes".
- Dopamine receptor signaling: D1 and D2 dopamine receptors can activate PI3K, creating context-dependent effects on neuronal survival.
Class I PI3Ks relevant to neuronal survival include:
| Isoform | Expression | Function in PD |
|---------|------------|----------------|
| PI3K p110α (PIK3CA) | Ubiquitous | Growth factor signaling, cell survival |
| PI3K p110β (PIK3CB) | High in brain | GPCR signaling, platelet-derived growth factor |
| PI3K p110δ (PIK3CD) | Immune cells | Neuroinflammation modulation |
| PI3K p110γ (PIK3CG) | Brain, microglia | GPCR signaling, microglial activation |
In dopaminergic neurons, p110α and p110β isoforms are most important for survival signaling, while p110γ in microglia modulates neuroinflammation.
¶ Akt Phosphorylation and Activation
Akt (protein kinase B) requires two phosphorylation events for full activation:
- Phosphorylation at Thr308 (by PDK1): Occurs when PI3K generates PIP3, recruiting Akt and PDK1 to the plasma membrane
- Phosphorylation at Ser473 (by mTORC2): Completes Akt activation and enables substrate access
In PD, multiple mechanisms impair Akt activation:
- Reduced PIP3 production: Enhanced PTEN activity or reduced PI3K signaling decreases membrane recruitment of Akt
- PP2A-mediated dephosphorylation: Alpha-synuclein oligomers activate protein phosphatase 2A (PP2A), which dephosphorylates Akt at both Thr308 and Ser473
- Oxidative stress: Reactive oxygen species can oxidize and inactivate Akt
Akt phosphorylates over 100 substrates, with key targets in PD including:
| Substrate |
Site |
Effect in PD Context |
| GSK-3β |
Ser9 |
Inhibits pro-apoptotic GSK-3β activity |
| mTOR |
Ser2448 |
Activates mTORC1, regulates autophagy |
| FOXO3a |
Ser253 |
Promotes nuclear export, blocks pro-apoptotic gene expression |
| BAD |
Ser136 |
Inhibits BAD-mediated apoptosis |
| ASK1 |
Ser83 |
Inhibits stress-activated apoptosis |
| Caspase-9 |
Ser196 |
Direct inhibition of apoptosis |
Glycogen synthase kinase-3 beta (GSK-3β) is one of the most important Akt substrates in PD pathogenesis:
- Normal function: Akt phosphorylates GSK-3β at Ser9, inhibiting its activity
- In PD: Reduced Akt activity leads to GSK-3β hyperactivation through diminished Ser9 phosphorylation
- Consequences of GSK-3β activation:
- Enhanced alpha-synuclein phosphorylation at Ser129, potentially altering aggregation dynamics
- Increased tau phosphorylation, contributing to comorbid tau pathology
- Activation of mitochondrial apoptosis pathways
- Promotion of neuroinflammation through NF-κB activation
Akt activates mTORC1, creating a therapeutic paradox in PD:
- Akt → mTORC1 activation inhibits autophagy, the primary mechanism for clearing alpha-synuclein aggregates
- mTORC1 inhibition (e.g., with rapamycin) induces autophagy but removes Akt-mediated pro-survival signaling
- Therapeutic implications: This creates a need for strategies that selectively induce autophagy without fully suppressing Akt survival signaling
Akt-mediated phosphorylation of FOXO3a promotes its nuclear export, preventing transcription of pro-apoptotic genes including:
- Bim (BCL2L11)
- Fas ligand (FASLG)
- PUMA (BBC3)
In PD, reduced Akt activity allows FOXO3a nuclear translocation, promoting expression of genes that accelerate dopaminergic neuron death.
¶ BAD and Mitochondrial Apoptosis
Unphosphorylated BAD sequesters anti-apoptotic Bcl-xL, enabling Bax/Bak-mediated mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and caspase activation. Akt phosphorylation of BAD at Ser136 prevents this pro-apoptotic cascade.
LRRK2 (leucine-rich repeat kinase 2) gain-of-function mutations (G2019S, R1441C/G/H) are among the most common genetic causes of familial PD:
- Effect on Akt: LRRK2 G2019S enhances phosphorylation of PTEN, reducing PIP3 levels and Akt activation
- Therapeutic target: LRRK2 inhibitors are in clinical development; their benefit may partly derive from restored Akt signaling
Alpha-synuclein interacts with PI3K/Akt signaling at multiple points:
- Oligomer toxicity: α-Syn oligomers activate PP2A, dephosphorylating and inactivating Akt
- Akt-mediated phosphorylation: Akt phosphorylates α-syn at Ser129, which may reduce aggregation but the relationship is complex
- Autophagy impairment: α-Syn accumulation inhibits autophagosome-lysosome fusion, compounding mTOR-mediated autophagy suppression
The PINK1/Parkin mitophagy pathway is regulated by Akt:
- Akt phosphorylates PINK1: Modulates its kinase activity and stability on damaged mitochondria
- Parkin activation: Akt signaling influences Parkin recruitment and ubiquitination of mitochondrial proteins
- Therapeutic relevance: Enhancing Akt signaling may support mitochondrial quality control
PD mitochondria show reduced Akt signaling:
- Complex I deficiency reduces PI3K/Akt activation
- Oxidative stress inactivates Akt
- Reduced mitochondrial biogenesis (via Akt/PGC-1α)
In PD microglia, PI3K/Akt signaling has dual roles:
- Pro-inflammatory: PI3K/Akt in M1 microglia promotes TNF-α, IL-1β, and IL-6 production
- Anti-inflammatory: Akt activation in astrocytes promotes anti-inflammatory phenotype (M2-like)
Cell-type-specific targeting is essential for therapeutic modulation.
MPTP, 6-OHDA, and rotenone models demonstrate:
- Reduced Akt phosphorylation in substantia nigra
- GSK-3β activation following Akt inhibition
- Neuroprotection by Akt activators (e.g., BDNF, GDNF)
- α-Syn transgenic models: Show impaired Akt signaling
- LRRK2 G2019S knock-in: Exhibits reduced Akt activation
- PINK1 knockout: Enhanced Akt dysregulation under stress
| Agent |
Mechanism |
Clinical Status |
| BDNF/TrkB agonists (7,8-DHF) |
Direct TrkB activation → PI3K/Akt |
Preclinical |
| GDNF delivery |
Ret receptor activation |
Phase 1/2 trials |
| Intranasal insulin |
Insulin receptor → PI3K/Akt |
Phase 2 trials |
| PI3K isoform-specific activators |
Direct PI3K activation |
Preclinical |
The PI3K/Akt-mTOR paradox suggests combination approaches:
- Akt activator + mTOR inhibitor: Activate survival signaling while inducing autophagy
- Akt activator + GSK-3β inhibitor: Bypass downstream inhibition
- AMPK activator (metformin): Inhibits mTOR independently of Akt, allowing autophagy without compromising survival
Several approaches target PI3K/Akt signaling in PD:
- Exenatide (GLP-1 agonist): Shown in Phase 2 trial to improve motor symptoms, partly through PI3K/Akt signaling
- NL-102 (PAK1 inhibitor): Targets downstream Akt effector, in development
- Inosine: Elevates urate, which may enhance Akt signaling
graph TD
subgraph Upstream["Upstream Activators"]
BDNF["BDNF / TrkB"]
GDNF["GDNF / Ret"]
INS["Insulin / IGF-1"]
end
BDNF --> PI3K
GDNF --> PI3K
INS --> PI3K
subgraph PI3K_Akt["PI3K/Akt Cascade"]
PI3K["PI3K<br/>p85/p110"] --> PIP3["PIP3"]
PIP3 --> PDK1["PDK1"]
PDK1 --> AKT1["Akt<br/>Thr308"]
AKT1 --> AKT2["Akt<br/>Ser473"]
end
subgraph Dysfunction["PD Pathological Alterations"]
ASYN["α-Syn Oligomers"] -->|"Activate PP2A"| AKT1
LRRK2["LRRK2 G2019S"] -->|"Enhance PTEN"| PIP3
OX["Oxidative Stress"] -->|"Inactivate"| AKT1
end
AKT2 --> GSK3B["GSK-3β<br/>Ser9 → INACTIVE"]
AKT2 --> MTOR["mTORC1<br/>ACTIVATED"]
AKT2 --> FOX["FOXO3a<br/>NUCLEAR EXPORT"]
AKT2 --> BADP["BAD<br/>Ser136 → INACTIVE"]
GSK3B -->|"When Active"| ASYNP["α-Syn Ser129<br/>Phosphorylation"]
GSK3B --> TAU["Tau<br/>Hyperphosphorylation"]
GSK3B --> APOP["Apoptosis"]
MTOR -->|"Inhibits"| AUTOPH["Autophagy"]
AUTOPH -->|"Impaired"| ASYNC["α-Syn<br/>Clearance"]
FOX -->|"Nuclear"| APOPG["Pro-apoptotic<br/>Gene Expression"]
BADP -->|"Inactive"| MITO["Mitochondrial<br/>Apoptosis Blocked"]
style AKT1 fill:#2ecc71,stroke:#27ae60,color:white
style AKT2 fill:#2ecc71,stroke:#27ae60,color:white
style GSK3B fill:#e74c3c,stroke:#c0392b,color:white
style MTOR fill:#f39c12,stroke:#e67e22,color:white
style ASYN fill:#9b59b6,stroke:#8e44ad,color:white